Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Simple Summary Tumor biomarkers are molecules at genetic or protein level, or certain
evaluable characteristics. These help in perfecting patient management. Over the past …

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid
cancers despite constitutive activation of the signaling correlates with disease recurrence …

Increasing evidence has indicated a close association between immune infiltration in cancer
and clinical outcomes. However, related research in thyroid cancer is still deficient. Our …

Background Papillary thyroid cancer has been associated with chronic inflammation. A
systematic understanding of immune cell infiltration in PTC is essential for subsequent …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Anticancer immunotherapy, in the form of immune checkpoint inhibition, is a paradigm shift
that has transformed the care of patients with different types of solid and hematologic …

Immune checkpoint inhibitors, namely anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal
antibodies, have emerged in the last decade as a novel form of cancer treatment, promoting …

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer. Particularly
the incidence of small clinically indolent tumors has been increasing significantly during the …

Immune-checkpoint inhibitors (ICI) are monoclonal antibodies which target molecules to
enhance antitumor response. Several adverse events have been described and the major …